Prostaglandin G/H synthase 1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin G/H synthase 1 as ChEMBL target CHEMBL2949, mapped to UniProt P05979. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Prostaglandin G/H synthase 1 matters
Prostaglandin G/H synthase 1 is reviewed as Prostaglandin G/H synthase 1 (UniProt P05979); the current evidence base includes 27 approved drugs, 3997 compounds, and 561 assays, with lead potency reaching pChEMBL 9.5.
Prostaglandin G/H synthase 1 Sequence length is 600 aa.
Review this target as Prostaglandin G/H synthase 1, mapped to UniProt P05979. Sequence length is 600 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 27 approved drugs, 3997 compounds, and 561 assays for this target. The dominant activity type is IC50. CHEMBL3774784 is the current potency anchor at pChEMBL 9.5.
Use CHEMBL3774784 as the tractability anchor when discussing potency (pChEMBL 9.5).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Prostaglandin G/H synthase 1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P05979, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3774784
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL500387
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL502799
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL503071
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL259972
|
8.8 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MELOXICAM
CHEMBL599
|
2000 |
|
|
CELECOXIB
CHEMBL118
|
1998 |
|
|
MOFEZOLAC
CHEMBL259972
|
1994 |
|
|
DICLOFENAC
CHEMBL139
|
1988 |
|
|
DICLOFENAC SODIUM
CHEMBL1034
|
1988 |
|
|
FLURBIPROFEN
CHEMBL563
|
1986 |
|
|
KETOPROFEN
CHEMBL571
|
1986 |
|
|
MECLOFENAMIC ACID
CHEMBL509
|
1980 |
|
|
NAPROXEN
CHEMBL154
|
1976 |
|
|
INDOMETHACIN
CHEMBL6
|
1965 |
|
|
THALIDOMIDE
CHEMBL468
|
1956 |
|
|
ASPIRIN
CHEMBL25
|
1950 |